NLRP3 and relapsing-remitting multiple sclerosis: Previous study on blood samples of patients with relapsing-remitting MS confirmed that the RNA expression levels of NLRP3 and IL-1β are upregulated in the acute phase and that the NLRP3 inflammasome is positively correlated with the response to interferon-β therapy in these patients [20].